4.7 Review

Endozepines and their receptors: Structure, functions and pathophysiological significance

Journal

PHARMACOLOGY & THERAPEUTICS
Volume 208, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2019.06.008

Keywords

Diazepam-binding inhibitor; Acyl-CoA-binding protein; Octadecaneuropeptide; Triakontatetraneuropeptide; Benzodiazepines; Translocator protein

Funding

  1. Agence Nationale de la Recherche (grant EZICROM) [ANR-16-CE14-0011]
  2. Institut National de la Sante et de la RechercheMedicale (Inserm)
  3. Normandy University (Rouen)
  4. LARC Neuroscience Network
  5. Institute for Research and Innovation in Biomedicine (IRIB)
  6. Region Normandy
  7. Canadian Institutes of Health Research
  8. John Stauffer Dean's Chair in Pharmaceutical Sciences (University of Southern California)
  9. Partenariat Hubert Curien (PHC Utique) [2016 34940PK]
  10. European Union

Ask authors/readers for more resources

The existence of specific binding sites for benzodiazepines (BZs) in the brain has prompted the search for endogenous BZ receptor ligands designated by the generic term endozepines. This has led to the identification of an 86-amino acid polypeptide capable of displacing [H-3]diazepam binding to brain membranes, thus called diazepam-binding inhibitor (DBI). It was subsequently found that the sequence of DBI is identical to that of a lipid carrier protein termed acyl-CoA-binding protein (ACBP). The primary structure of DBI/ACBP has been well preserved, suggesting that endozepines exert vital functions. The DBI/ACBP gene is expressed by astroglial cells in the central nervous system, and by various cell types in peripheral organs. Endoproteolytic cleavage of DBI/ACBP generates several bioactive peptides including a triakontatetraneuropeptide that acts as a selective ligand of peripheral BZ receptors/translocator protein, and an octadecaneuropeptide that activates a G protein-coupled receptor and behaves as an allosteric modulator of the GABA A R. Although DBI/ACBP is devoid of a signal peptide, endozepines are released by astrocytes in a regulated manner. Consistent with the diversity and wide distribution of BZ-binding sites, endozepines appear to exert a large array of biological functions and pharmacological effects. Thus, intracerebroventricular administration of DBI or derived peptides induces proconflict and anxiety-like behaviors, and reduces food intake. Reciprocally, the expression of DBI/ACBP mRNA is regulated by stress and metabolic signals. In vitro, endozepines stimulate astrocyte proliferation and protect neurons and astrocytes from apoptotic cell death. Endozepines also regulate neurosteroid biosynthesis and neuropeptide expression, and promote neurogenesis. In peripheral organs, endozepines activate steroid hormone production, stimulate acyl chain ceramide synthesis and trigger pro-inflammatory cytokine secretion. The expression of the DBI/ACBP gene is enhanced in addiction/withdrawal animal models, in patients with neurodegenerative disorders and in various types of tumors. We review herein the current knowledge concerning the various actions of endozepines and discuss the physiopathological implications of these regulatory gliopeptides. (C) 2019 Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available